After Pfizer outbid Gilead for Medivation last September, Todd Hagopian named 4 companies Gilead might go after next. Kite Pharma, then trading at about $55, was among them. On Monday, Gilead acquired KITE for $180 per share. If you missed KITE, who might get gobbled up next?
from Forbes Real Time //www.forbes.com/sites/kenkam/2017/08/30/after-gileads-acquisition-of-kite-who-gets-gobbled-up-next/
via IFTTT
No comments:
Post a Comment